<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833805</url>
  </required_header>
  <id_info>
    <org_study_id>J1688</org_study_id>
    <secondary_id>IRB00107139</secondary_id>
    <nct_id>NCT02833805</nct_id>
  </id_info>
  <brief_title>NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia</brief_title>
  <official_title>A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary objective is to determine if it is feasible for previously untreated severe
      aplastic anemia (SAA) patients to be transplanted using non-myeloablative conditioning and
      post transplantation cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical trial of upfront bone marrow transplantation for patients with SAA who do
      not have a fully human leukocyte antigen (HLA) matched donor. The trial uses a conditioning
      regimen which has been successful in the refractory and relapsed setting to maximize
      engraftment and post transplant therapy to minimize graft versus host disease (GVHD). This
      would be used here in patients who have not yet undergone immunosuppressive therapy for their
      SAA or are thought to be unlikely to respond to immunosuppressive therapy for SAA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival and engraftment at one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of enrolled participants who receive BMT, achieve engraftment, and are alive at one year post BMT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive at one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of neutrophil recovery</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who have recovered neutrophil counts at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of platelet recovery</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who have recovered platelet counts at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience primary graft failure by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary graft failure</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience secondary graft failure by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades II-IV acute GVHD, Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Percentage of participants who experience grade II, III, or IV acute GVHD by Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades III-IV acute GVHD, Day 100</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience grade III or IV acute GVHD by Day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, one year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who experience chronic GVHD by one year after BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate full donor chimerism</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of participants with full donor chimerism at Day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate GVHD-free relapse-free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive, without relapse, and without GVHD at 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate transplant-related mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants deceased for reasons related to BMT at 1 year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Anti-thymocyte globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Days -6 through -2: 30 mg/m^2 IV daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Cy</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>Day -1: 200 centigray (cGy) in a single fraction</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Start on Day 5 through Day 365</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>FK506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)</description>
    <arm_group_label>Bone marrow transplant</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of inherited or acquired severe aplastic anemia (SAA)

          -  One of the following available donors:

               1. HLA-haploidentical relative

               2. If recipient is &gt;= 40 years old, may use HLA-matched related donor

               3. For recipients with inherited bone marrow failure syndromes (IBMFS) with clear
                  evidence of same disorder in potential related donors, may use 10/10 matched
                  unrelated donor

          -  Recipient and/or legal guardian must sign protocol informed consent

          -  Donor must be willing to donate bone marrow

          -  Left ventricular ejection fraction (LVEF) &gt;= 40%. For recipients &lt; 13 years old,
             shortening fraction &gt;= 26% may be used instead.

          -  Bilirubin &lt; 3 x upper limit of normal (ULN) for age, unless patient has Gilbert's
             disease

          -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 5 x ULN for age

          -  For patients &gt;= 13 years old: estimated creatinine clearance &gt; 50 mL/min using
             Cockcroft-Gault formula and actual body weight

          -  For patients &gt;= 1 but &lt; 13 years old: glomerular filtration rate (GFR) estimated by
             updated Schwartz formula &gt;= 90 mL/min/1.73 m^2. If estimated GFR is &lt; 90 mL/min/1.73
             m^2, 24-hour measured creatinine clearance must be &gt; 50 mL/min/1.73 m^2.

          -  For patients &gt;= 8 years old, diffusing capacity of the lung for carbon monoxide (DLCO)
             (corrected for hemoglobin) &gt; 40%; forced expiratory volume at one second (FEV1) &gt; 50%;
             forced vital capacity (FVC) &gt; 50%

          -  For patients &lt; 8 years old or unable to undergo pulmonary function testing: no
             evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation &gt; 92%
             on room air

          -  Karnofsky/Lansky status (depending on age) &gt;= 70%

          -  Females and males of childbearing potential must agree to practice 2 effective methods
             of contraception at the same time. If unwilling, they must agree to complete
             abstinence.

        Exclusion Criteria:

          -  Previous administration of immunosuppressive therapy for SAA.

          -  Fanconi anemia. At minimum, this diagnosis must be excluded by diepoxybutane (DEB) or
             equivalent testing on peripheral blood or marrow in patients &lt; 30 years old.

          -  Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome
             (pre-MDS) or MDS on bone marrow examination

          -  Presence of anti-donor antibodies

          -  Prior allogeneic stem cell transplant

          -  Prior solid organ transplant

          -  Uncontrolled bacterial, viral, or fungal infection

          -  HIV seropositivity

          -  Active hepatitis B or C infection determined by serology and/or nucleic acid testing
             (NAT)

          -  Pregnancy or active breastfeeding

          -  Prior malignancies except: resected basal carcinoma or treated cervical carcinoma in
             situ; cancer treated with curative intent &gt; 5 years previously. Other prior cancers
             will not be allowed unless approved by the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy E DeZern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy E DeZern, MD</last_name>
    <phone>410-502-7208</phone>
    <email>adezern1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy E DeZern, MD</last_name>
      <phone>410-502-7208</phone>
      <email>adezern1@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunosuppression</keyword>
  <keyword>nonmyeloablative</keyword>
  <keyword>non-myeloablative</keyword>
  <keyword>allogeneic</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>bone marrow</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>thymoglobulin</keyword>
  <keyword>ATG</keyword>
  <keyword>fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

